临床试验

Histotripsy for Ablation of Liver Tumours in Asia

NCT：NCT07428356 · RECRUITING

NCT编号NCT07428356

状态RECRUITING

开始日期2025-11-07

完成时间2029-05-07

SponsorNational Cancer Centre, Singapore (OTHER)

First posted2026-02-23

Last updated2026-10-08

简要摘要

The HALT study aims to evaluate histotripsy in an Asian population for both primary (HCC, CCA) and secondary liver malignancies with liver-limited or oligoprogressive disease. In addition to safety and local control, the study incorporates translational endpoints including immune profiling (PBMCs, cytokines), microbiome shifts, and optional tumour biopsies. This trial will provide critical data on the feasibility, tolerability, and biological impact of histotripsy in a region with the highest burden of liver cancer.

官方来源

在 ClinicalTrials.gov 上查看 →

数据来自 ClinicalTrials.gov API。有关最新状态，请参阅官方记录。